TLR3 controls constitutive IFN-β antiviral immunity in human fibroblasts and cortical neurons

Daxing Gao

Michael S Diamond

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
TLR3 controls constitutive IFN-β antiviral immunity in human fibroblasts and cortical neurons

Daxing Gao, … , Jean-Laurent Casanova, Shen-Ying Zhang


**Graphical abstract**

Find the latest version:

https://jci.me/134529/pdf
Human herpes simplex virus 1 (HSV-1) encephalitis can be caused by inborn errors of the TLR3 pathway, resulting in impairment of CNS cell-intrinsic antiviral immunity. Deficiencies of the TLR3 pathway impair cell-intrinsic immunity to vesicular stomatitis virus (VSV) and HSV-1 in fibroblasts, and to HSV-1 in cortical but not trigeminal neurons. The underlying molecular mechanism is thought to involve impaired IFN-α/β induction by the TLR3 recognition of dsRNA viral intermediates or by-products. However, we show here that human TLR3 controls constitutive levels of IFNB mRNA and secreted bioactive IFN-β protein, and thereby also controls constitutive mRNA levels for IFN-stimulated genes (ISGs) in fibroblasts. Tlr3−/− mouse embryonic fibroblasts also have lower basal ISG levels. Moreover, human TLR3 controls basal levels of IFN-β secretion and ISG mRNA in induced pluripotent stem cell-derived cortical neurons. Consistently, TLR3-deficient human fibroblasts and cortical neurons are vulnerable not only to both VSV and HSV-1, but also to several other families of viruses. The mechanism by which TLR3 restricts viral growth in human fibroblasts and cortical neurons in vitro and, by inference, by which the human CNS prevents infection by HSV-1 in vivo, is therefore based on the control of early viral infection by basal IFN-β immunity.

Introduction

TLR3 on endosomes recognizes double-stranded RNA (dsRNA) intermediates or by-products generated during viral infection. TLR3 signaling leads to the activation of IFN regulatory factor 3 (IRF3), NF-κB, and ATF/c-jun, promoting the induction of antiviral IFNs and downstream IFN-stimulated genes (ISGs) (1–4). The discovery of inborn errors of human TLR3 and its pathway in children with herpes simplex virus 1 (HSV-1) encephalitis (HSE) led to the suggestion that TLR3 serves as a key sensor for HSV-1 replication in the CNS (5–7). Childhood HSE is a rare, sporadic, and life-threatening complication of primary infection with HSV-1 in which the virus replicates in the CNS. HSV-1 infection is ubiquitous in the general population. The virus resides in the trigeminal (TG) ganglion, where it remains latent, but can later reactivate to cause benign herpes labialis or other rare complications, including HSE (8). The pathogenesis of HSE remained unexplained until our description of the first genetic etiologies for this disease (9, 10). Germline HSE-causing mutations have since been reported in 7 genes of the TLR3 pathway (TLR3, UNC93B1, TRIF, TRAF3, TBK1, IRF3, NEMO) and 2 genes of the IFN-α/β receptor pathway (IFNAR1, STAT1) (9–17). UNC-93B1 is a membrane-bound molecule that regulates the signaling of endosomal TLR3, TLR7, TLR8, and TLR9 by binding to their transmembrane domains and

Authorship note: MJ.C, PZ, and OH contributed equally to this work. VB, MH, and JC contributed equally to this work. JLC and SYZ contributed equally to this work.

Conflict of Interest: The authors have declared that no conflict of interest exists.

Copyright: © 2021, American Society for Clinical Investigation.

Submitted: October 24, 2019; Accepted: November 5, 2020; Published: January 4, 2021.

maintaining TLR3 expression (18–21). TRIF is the sole adaptor of TLR3, whereas TRAF3, TBK1, IRF3, and NEMO are key molecules required for the TLR3-TRIF-dependent induction of antiviral IFNs (7). Candidate mutations in other genes of the pathway have also been reported (22). Mutations of TLR3 pathway genes have been shown to impair the TLR3-dependent induction of antiviral IFNs, whereas IFNAR1 and STAT1 mutations impair cellular responses to type I IFNs. Collectively, these findings suggest that HSE can result from the impaired production of IFN-α/β and/or IFN-λ in response to TLR3 stimulation by HSV-1 in the CNS.

This hypothesis was initially supported by experiments conducted in dermal fibroblasts infected with HSV-1 and another neurotropic virus, vesicular stomatitis virus (VSV), an ssRNA virus typically innocuous in humans, chosen for these studies because it is highly cytopathic and induces IFN more effectively than HSV-1 in these cells (23). Fibroblasts with TLR3 signaling deficiencies are highly cytopathic and induces IFN more effectively than HSV-1 neurotropic virus, vesicular stomatitis virus (VSV), an ssRNA virus in response to TLR3 stimulation by HSV-1 in the CNS. IFN-λ-β-α and/or HSE can result from the impaired production of IFN-α responses to type I IFNs. Collectively, these findings suggest that viral IFNs, whereas IFN-α/β can be induced by extracellular poly(I:C) stimulation, which activates TLR3 in endosomes (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI134529DS1), or intracellular poly(I:C) stimulation, which activates RIG-I and MAD5 in the cytosol (Supplemental Figure 1) (28). We hypothesized that, if the higher levels of viral growth and cell death observed in TLR3-deficient cells were due to an impairment of virus-induced IFN production, then a potent IFN-inducing stimulus would rescue viral susceptibility. We made use of a natural mutant of VSV, VSV-M51R, which induces IFN very strongly in most of the cells tested, much more so than VSV-WT (32, 33).

We first assessed the production of IFN-β and -λ following infection with VSV-WT and -M51R at various MOIs for 24 hours, in similar virus 40 (SV-40) T antigen–transformed fibroblasts (SV-40 fibroblasts) from a healthy control, a patient with HSE with autosomal recessive (AR) UNC-93B deficiency (UNC-93B–/–), and a patient with HSE with AR TLR3 deficiency (TLR3–/–). Surprisingly, UNC-93B–/– and TLR3–/– cells produced about 30 times more IFN-β than healthy control cells after 24 hours of infection with VSV-M51R at a MOI of 0.01 (Figure 1A). Similar results were obtained for IFN-λ (as measured by ELISA, which recognizes all 3 types of IFN-λ, IFNλ1, IFNλ2, and IFNλ3), but not other subtypes of antiviral IFNs, which were detected by ELISA in healthy control cells. We then investigated whether our findings also applied to HSV-1 infection in iPSC-derived cortical and TG neurons.

Results

**RIG-I-dependent overproduction of IFN-β and -λ in response to VSV-M51R in TLR3-deficient fibroblasts.** In human fibroblasts, high levels of mRNA for IFN-β and IFN-λ (including all 3 types of IFN-λ, IFNλ1, IFNλ2, and IFNλ3), but not other subtypes of antiviral IFNs, can be induced by extracellular poly(I:C) stimulation, which activates TLR3 in endosomes (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI134529DS1), or intracellular poly(I:C) stimulation, which activates RIG-I and MAD5 in the cytosol (Supplemental Figure 1) (28). We hypothesized that, if the higher levels of viral growth and cell death observed in TLR3-deficient cells were due to an impairment of virus-induced IFN production, then a potent IFN-inducing stimulus would rescue viral susceptibility. We made use of a natural mutant of VSV, VSV-M51R, which induces IFN very strongly in most of the cells tested, much more so than VSV-WT (32, 33).

We first assessed the production of IFN-β and -λ following infection with VSV-WT and -M51R at various MOIs for 24 hours, in similar virus 40 (SV-40) T antigen–transformed fibroblasts (SV-40 fibroblasts) from a healthy control, a patient with HSE with autosomal recessive (AR) UNC-93B deficiency (UNC-93B–/–), and a patient with HSE with AR TLR3 deficiency (TLR3–/–). Surprisingly, UNC-93B–/– and TLR3–/– cells produced about 30 times more IFN-β than healthy control cells after 24 hours of infection with VSV-M51R at a MOI of 0.01 (Figure 1A). Similar results were obtained for IFN-λ (as measured by ELISA, which recognizes all 3 types of IFN-λ, IFNλ1, IFNλ2, and IFNλ3), but not other subtypes of antiviral IFNs, which were detected by ELISA in healthy control cells. We then investigated whether our findings also applied to HSV-1 infection in iPSC-derived cortical and TG neurons. Unlike iPSC-derived cortical neurons, iPSC-derived peripheral TG neurons from healthy donors control HSV-1 as poorly as poly(I:C)-unresponsive TLR3-deficient TG neurons, in terms of viral growth (26). Pretreatment with IFN-α or -β, but not IFN-λ, rescues susceptibility to viral infections in both types of TG neurons, whereas pretreatment with poly(I:C) rescues only control TG neurons, in which IFNs and ISGs are induced in response to TLR3-dependent poly(I:C) stimulation. These data indicate that TG neurons are vulnerable to HSV-1 in the absence of preemptive stimulation via TLR3 or IFN-α/β receptors, whereas control cortical neurons display TLR3-dependent constitutive resistance that is sufficiently strong to block incoming HSV-1 in the absence of prior antiviral signals. This experimental observation in vitro is consistent with HSV-1 infecting TG neurons and establishing latency in these cells, but not in cortical neurons in vivo in most individuals (27). Overall, these findings suggest a cellular model of HSE with a TLR3-dependent IFN-mediated phenotype in fibroblasts and iPSC-derived cortical but not TG neurons. However, the molecular basis of these 2 cellular phenotypes in vitro and of HSE in vivo remained unexplained. Indeed, although both HSV-1 and VSV produce dsRNAs (28, 29), HSV-1 recognition depends largely on the cGAS DNA sensor in mouse fibroblasts and myeloid cells (30), whereas VSV recognition in mouse fibroblasts is dependent on RIG-1 (31). It therefore remained unclear whether TLR3 actually recognizes dsRNA intermediates or by-products generated during the infection of fibroblasts and cortical neurons with HSV-1 and VSV, or whether it controls the IFN-mediated immunity of these cells against these viruses by other mechanisms. As a first step toward addressing this question, we performed a comprehensive analysis of the connection between IFN induction and VSV infection in human fibroblasts. We then investigated whether our findings also applied to HSV-1 infection in iPSC-derived cortical and TG neurons.
knockdown of RIG-I or its downstream signaling molecule MAVS (34–37), the production of IFN-β in response to VSV-M51R infection, or to transfected poly(I:C) and 7sk-as, was much weaker in RIG-I– or MAVS-knockdown UNC-93B–/– cells than in those transduced with a control scrambled RNA, indicating the essential role of RIG-I in sensing VSV-M51R (Supplemental Figure 3, A and B). Thus, VSV-M51R can induce IFN-β or IFN-λ via RIG-I in UNC-93B–/– and TLR3–/– fibroblasts, and, paradoxically, UNC-93B–/– and TLR3–/– cells respond to VSV-M51R by producing markedly larger amounts of IFN-β and -λ than control cells.

The hyper-IFN response to VSV-M51R in TLR3-deficient fibroblasts is triggered by enhanced viral replication. We then investigated whether RIG-I was hyperactive in UNC-93B–/– fibroblasts, which would account for IFN overinduction as a means of compensating for the lack of TLR3 signaling. We overcame the problem of the confounding effect of a larger viral stimulus in UNC-93B–/– cells by transfecting the fibroblasts with total cellular RNA isolated from VSV-WT– or VSV-M51R–infected Vero cells (vRNA). IFN-β production levels were almost identical between UNC-93B–/– and healthy control cells stimulated by transfection with vRNA (Supplemental Figure 3C). As no viral proteins antagonistic to IFN were produced, VSV-WT and VSV-M51R RNA induced IFN-β to similar levels (Supplemental Figure 3C). This result suggests that the RIG-I pathway is equally active in the cells of patients with UNC-93B deficiency and healthy controls. Moreover, when we coinfected fibroblasts with both VSV-WT and VSV-M51R, the high levels of IFN-β production induced by the M51R virus were completely abolished by coinfection with VSV-WT (Supplemental Figure 3D) (38). This suggests that the inability to block mRNA export from the nucleus, and thus, to abolish IFN production by VSV-WT, is responsible for this phenomenon rather than the stimulation, by VSV-M51R, of an additional signaling pathway different from that stimulated by the WT virus (39). However, consistent with the high levels of virus-triggered IFN-β and IFN-λ production in UNC-93B–/– and TLR3–/– fibroblasts, we detected substantially more dsRNA in the cells of patients with UNC-93B and NEMO deficiency than in control fibroblasts (Figure 1C), 8 hours after VSV-WT or -M51R infection, by Western blotting with anti–dsRNA antibody (28). The high levels of dsRNA are also consistent with the previously known rapid VSV-WT replication in UNC-93B–/– and TLR3–/– fibroblasts, which was confirmed by determining VSV glycoprotein (VSV-G) mRNA levels by quantitative real-time PCR (RT-qPCR) (Supplemental Figure 3E). Interestingly, the induction of IFNB mRNA by VSV-WT was detectable only at late time points (not at the 6 hour time point) (Supplemental Figure 3F), suggesting that viral replication is required for IFN induction. Indeed, this enhanced production of IFN in UNC-93B–/– and TLR3–/– cells required an actively replicating virus, as the ultraviolet irradiation of VSV-WT and -M51R blocked their stimulatory effect (Supplemental Figure 3G). Thus, coinfection of fibroblasts with both VSV-WT and VSV-M51R, the high levels of IFN-β production induced by the M51R virus were completely abolished by coinfection with VSV-WT (Supplemental Figure 3D) (38). This suggests that the inability to block mRNA export from the nucleus, and thus, to abolish IFN production by VSV-WT, is responsible for this phenomenon rather than the stimulation, by VSV-M51R, of an additional signaling pathway different from that stimulated by the WT virus (39). However, consistent with the high levels of virus-triggered IFN-β and IFN-λ production in UNC-93B–/– and TLR3–/– fibroblasts, we detected substantially more dsRNA in the cells of patients with UNC-93B and NEMO deficiency than in control fibroblasts (Figure 1C), 8 hours after VSV-WT or -M51R infection, by Western blotting with anti–dsRNA antibody (28). The high levels of dsRNA are also consistent with the previously known rapid VSV-WT replication in UNC-93B–/– and TLR3–/– fibroblasts, which was confirmed by determining VSV glycoprotein (VSV-G) mRNA levels by quantitative real-time PCR (RT-qPCR) (Supplemental Figure 3E). Interestingly, the induction of IFNB mRNA by VSV-WT was detectable only at late time points (not at the 6 hour time point) (Supplemental Figure 3F), suggesting that viral replication is required for IFN induction. Indeed, this enhanced production of IFN in UNC-93B–/– and TLR3–/– cells required an actively replicating virus, as the ultraviolet irradiation of VSV-WT and -M51R blocked their stimulatory effect (Supplemental Figure 3G). Thus,
kinetics and virus-induced cell death. Surprisingly, although VSV-M51R complemented the IFN phenotype, with IFN levels even exceeding those observed in controls, this potent induction of IFN production by the virus did not decrease viral replication and cell mortality in TLR3−/− or UNC-93B−/− SV-40 fibroblasts upon infection with VSV-M51R at a MOI of 1, from 0.5 hour to 24 hours after infection. Both the WT and M51R viruses replicated much more rapidly in UNC-93B−/− and TLR3−/− cells than in control cells, and, by 6 hours after infection, there was at least a 100-fold difference in titer (Figure 2, A and B), whereas IFN induction was not readily detectable at this time point (Supplemental Figure 2, A–C). We then measured VSV replication, by assessing viral VSV-G RNA levels in fibroblasts from patients with inborn errors of TLR3 (TLR3, UNC93B1, NEMO) or IFN (STAT1, STAT2) immunity (40, 41), comparing these levels with those in WT control cells. VSV levels were markedly higher in the cells of all patients 16 hours after infection (Figure 2, C and D; and Supplemental Figure 4, A and B). Moreover, cell death rates were greater in UNC-93B−/− cells than in control cells after 24 hours of VSV-WT or -M51R infection (Figure 2, E and F), despite the extremely high levels of IFN production following infection with VSV-M51R (Figure 1, A and B; Supplemental Figure 2, A–C). Thus, although the production of larger amounts of immunostimulatory viral replication intermediates in TLR3 pathway-deficient fibroblasts, such as dsRNA (Figure 1C), led to enhanced IFN production by the patients’ cells upon infection with VSV-M51R, this enhanced IFN production was not sufficient to protect these cells against viral replication, which reached very high levels before IFN production was induced by the virus.

General antiviral defect in fibroblasts with deficiencies of the TLR3 and IFN signaling pathways. We then assessed the susceptibility of UNC-93B−/− and TLR3−/− fibroblasts to other viruses, which may or may not rely on TLR3 for virus-triggered IFN induction, by evaluating viral replication and virus-induced cell death. We found that another ssRNA virus, human parainfluenza virus 3 (hPIV3), like VSV, replicated faster and to higher titers in UNC-93B−/− and TLR3−/− fibroblasts (Figure 3B). As a result, viral cytopathicity was also higher in UNC-93B−/− and TLR3−/− fibroblasts (Figure 3B). IFN-β production was similar in control and TLR3- or UNC-93B-deficient fibroblasts infected with...
IFN pathway–deficient cells than in control cells (Figure 3E; and Supplemental Figure 4C), 16 hours after infection, whereas IFNB and IFNL mRNA induction was detected 24 hours after infection (Supplemental Figure 4, D and E). Overall, these data indicate that fibroblasts with deficiencies of the TLR3 and IFN signaling pathways are highly susceptible to infection with at least 3 RNA viruses (VSV, hPIV3, and EMCV) and one DNA virus (HSV-1), despite a high level of IFN production induced by VSV-M51R and the normal induction of IFN production by hPIV3 and EMCV in TLR3 pathway–deficient cells. This is paradoxical, as poor IFN production by these cells upon infection with VSV-WT and HSV-1 had been thought to underlie the cellular vulnerability to both viruses.

Low basal levels of IFN and ISG expression in fibroblasts with TLR3-IFN signaling deficiencies. Our previous and current data show that the prior treatment (but not treatment at the time of infection) of TLR3 signaling–deficient fibroblasts with recombinant IFN-α2b or -β, but not IFN-λ, protects them against VSV-WT and -M51R, or HSV-1 replication and virus-induced cell death (Supplemental Figure 5A) (10). In this study, we also found that TLR3 signaling–deficient cells sustained very high levels of virus replication before the induction of IFN production in response to viral infection (Figure 3E; and Supplemental Figure 4, C–E). We therefore hypothesized that viral replication might be limited in control cells by basal levels of IFNs constitutively expressed in a TLR3-dependent manner. We tested this hypothesis, first by assessing basal levels of IFN and ISG expression in fibroblasts with TLR3-IFN signaling deficiencies. We subsequently challenged fibroblasts with encephalomyocarditis virus (EMCV), another RNA virus that has been shown to induce IFN production in an MDA5-dependent manner in MEFs (31, 42), and that, like hPIV3, induces normal levels of IFN production in TLR3-deficient human fibroblasts (10, 13). EMCV also replicated to high levels in cells with TLR3 pathway deficiencies (TLR3, UNC93B1, NEMO) or IFN pathway deficiencies (STAT1, STAT2) (Figure 3D). Finally, consistent with our previous reports of enhanced HSV-1 replication in TLR3 pathway–deficient fibroblasts (9, 10), we detected higher levels of HSV-1 viral ICP27 RNA in TLR3 pathway–deficient or control cells (Figure 3E; and Supplemental Figure 4C), 16 hours after infection, whereas IFNB and IFNL mRNA induction was detected 24 hours after infection (Supplemental Figure 4, D and E). Overall, these data indicate that fibroblasts with deficiencies of the TLR3 and IFN signaling pathways are highly susceptible to infection with at least 3 RNA viruses (VSV, hPIV3, and EMCV) and one DNA virus (HSV-1), despite a high level of IFN production induced by VSV-M51R and the normal induction of IFN production by hPIV3 and EMCV in TLR3 pathway–deficient cells. This is paradoxical, as poor IFN production by these cells upon infection with VSV-WT and HSV-1 had been thought to underlie the cellular vulnerability to both viruses.
ciencies, in which responses to all TLRs except TLR3 were impaired, displayed normal levels of IFNs and ISGs mRNA (Supplemental Figure 5C). Basal levels of mRNA for IFNB, IFNL1, CXCL10, and IFI44L were also lower in SV-40 fibroblasts from patients with STAT1 and STAT2 deficiency whose IFN response signaling is impaired than in control cells (Figure 4, A–D) (40, 41). The immortalization of fibroblasts with SV-40 T antigen has been reported to affect IFN immunity (43). We then analyzed the transcriptomes of control, TLR3−/−, and STAT1−/− primary fibroblasts by RNA sequencing (RNA-Seq) to rule out the possibility that the apparently TLR3-IFN signaling-related basal levels of IFN and ISG were an SV-40 fibroblast-specific phenomenon. We found that mRNA for 716 fibroblastic ISGs, but not IFNs, was detectable in control primary fibroblasts in basal conditions. mRNA levels were significantly lower in both TLR3−/− and STAT1−/− primary fibroblasts than in control cells for 43 of the 225 differentially expressed ISGs, whereas 13 ISGs were upregulated in these cells relative to control cells (Figure 4E, Supplemental Figure 5D, Supplemental Table 1). An analysis, with DAVID software (44), of the 43 ISGs with low basal expression levels further confirmed the significant downregulation of type I IFN signaling pathway genes and antiviral immune genes in TLR3−/− and STAT1−/− primary fibroblasts (Supplemental Table 2). Thus, TLR3 and IFN signaling deficiencies have a profound impact on basal IFN-β production and ISG expression in SV-40–transformed and primary fibroblasts in the absence of exogenous stimulation, demonstrating the role of TLR3 in maintaining constitutive antiviral gene expression.

Low basal levels of IFN production underlie the enhanced viral growth in TLR3-deficient fibroblasts. We assessed the importance of basal levels of IFN production in control cells, by neutralizing the IFNs and assessing the impact of this intervention on VSV replication. We cultured UNC-93B−/−, STAT1−/−, and control SV-40

Figure 4. Impact of TLR3 signaling deficiencies on basal IFN-related gene expression. mRNA levels of IFNB (A), IFNL1 (B), CXCL10 (C), and IFI44L (D) (relative to GAPDH) in unstimulated fibroblasts from healthy controls (C1–C4) and individuals deficient for TLR3-IFN signaling, as quantified by RT-qPCR with normalization against C1. Representative data from 3 independent experiments are shown. The error bars indicate SDs of triplicate measurements. (E) Gene expression profile of the ISGs differentially expressed in patients with STAT1 (blue bar) and TLR3 (orange bar) deficiencies, relative to mean expression levels in controls, as assessed by RNA-Seq. The heatmap shows the log fold-change in ISG expression, with red indicating upregulation and green downregulation. P values were obtained for likelihood ratio tests by comparing each patient’s fibroblasts with control fibroblasts (A–D), and the respective P values are indicated. **P < 0.01, ***P < 0.001.
fibroblasts in the presence or absence of neutralizing polyclonal antibodies (NAbs) raised against IFN-α, -β, and -λ (IFN Nab). We measured VSV-WT and VSV-M51R growth kinetics over 24 hours. Viral titers were similar in UNC-93B–/– and STAT1–/– fibroblasts with and without NAbs. By contrast, the growth of VSV in control fibroblasts was greater at 8 and 24 hours after infection in the presence of anti-IFN NAbs than in their absence (Figure 5, A and B), suggesting a substantial contribution of basal IFN production, which

---

**Figure 5. Constitutive IFN-β production in fibroblasts is TLR3 dependent.** Replication of VSV-WT (A) and VSV-M51R (B) in fibroblasts from a healthy control (C1) or patients with UNC-93B or STAT1 deficiency, cultured in the presence or absence of neutralizing antibodies against IFN-α, -β, and -λ (IFN Nab). (C) CXCL10 mRNA levels in unstimulated fibroblasts after treatment with IFN Nab for 24 hours. (D) IFN-β and IFN-λ1 (IL-29) mRNA levels in TLR3–/– fibroblasts transfected with WT TLR3, measured by RT-qPCR and normalized against GUS expression. Replication of VSV-WT (E) and VSV-M51R (F) in TLR3–/– fibroblasts stably transfected with empty vector (+EV) or WT TLR3 (+TLR3). Replication of VSV-WT (G) and VSV-M51R (H) in UNC-93B–/– fibroblasts stably transfected with empty vector or WT UNC-93B (+UNC-93B). Representative results are shown for 3 (A, B, E–H) or 2 (C–D) independent experiments. The error bars indicate SDs of biological triplicates (C, D) or the SEM of biological triplicates (A, B, E–H). P values were obtained through log transformation followed by 1-way ANOVA and subsequent Tukey’s multiple comparison tests, and the respective P values are indicated. **P < 0.01, ***P < 0.001, ****P < 0.0001.
levels similar to those in a healthy control following the expression of WT TLR3 (Figure 5D). In TLR3–/– cells complemented with WT TLR3, replication rates for VSV-WT and VSV-M51R were lower than those in nontransfected TLR3–/– cells or in TLR3–/– cells transfected with an empty vector (Figure 5, E and F). A similar rescue was observed in the growth curve of VSV-WT and VSV-M51R in WT UNC-93B–expressing UNC-93B –/– fibroblasts (Figure 5, G and H). Collectively, these experiments demonstrate that a lack of TLR3 signaling results in a deficiency of cell-intrinsic, constitutive antiviral IFN responses in fibroblasts, leading to early viral replication that may overwhelm the activity of RIG-I–dependent IFN production, which is induced later in response to viral replication.

**Basal IFN-β production by control cells restricts viral growth.** In human fibroblasts, IFNB was the only interferon gene strongly expressed in basal conditions, and only IFNB, IFNL1, IFNL2, and IFNL2 displayed a strong induction of expression upon activation of the TLR3 or MAVS pathway (Supplemental Figure 1). However, these cells did not express the receptor for type III IFNs (Supplemental Figure 6A). We hypothesized that the basal production of small amounts of IFN-β by healthy control cells can rescue the TLR3-deficient cell phenotype. We evaluated the effects of basal IFN, by stimulating patients’ SV-40 fibroblasts with conditioned medium from healthy control unstimulated cell cultures. This medium effectively decreased the growth of VSV-M51R (Figure 6A) and HSV-1 (Figure 6B, Supplemental Figure 6B) at 24 hours in TLR3–/– and UNC-93B–/– cells from patients, to levels below those in cells treated with medium from TLR3–/– and UNC-93B–/– fibroblasts, with virus titers close to those measured in control cells.

Moreover, mRNA levels for ISGs, including CXCL10, MxA, and RIG-I, were upregulated in the patients’ fibroblasts by stimulation with conditioned medium from healthy controls, but not with conditioned medium from TLR3–/– and UNC-93B–/– fibroblasts (Figure 6C, Supplemental Figure 6C). Fibroblasts are unable to respond to IFN-λ, probably because they lack IFNLR expression (Supplemental Figure 6A) (45). However, the pretreatment of TLR3 sig-
naling–deficient fibroblasts with either IFN-β or IFN-α2b can rescue resistance to viral infection, consistent with the relatively high levels of IFNAR expression (Supplemental Figure 6A). We found that IFN-β NAbs abolished both the protection against VSV-M51R growth and ISG induction conferred by the conditioned culture medium from control fibroblasts (Supplemental Figure 6, D and E), demonstrating that IFN-β is the protective cytokine in this context. STAT1−/− fibroblasts failed to upregulate ISGs when treated with conditioned medium from healthy controls (Supplemental Figure 6E), suggesting that the IFN signaling pathway is essential for the maintenance of basal ISG expression by basal IFN levels. Thus, TLR3-dependent, constitutive IFN-β production governs intrinsic antiviral immunity in human fibroblasts.

**TLR3 also controls constitutive antiviral IFN immunity in mouse fibroblasts.** We investigated whether TLR3-dependent constitutive IFN responses also governed cell-intrinsic constitutive antiviral immunity in MEFs. In mice, spontaneous IFN-α/β production in vivo in the absence of viral infection primes and enhances the immune response (46–48). We performed RNA-Seq on WT primary MEFs and Tlr3−/− MEFs to determine whether TLR3 plays a critical role in controlling cell-intrinsic basal IFN and antiviral immunity in mouse cells. Basal mRNA levels were significantly lower in Tlr3−/− MEFs than in Tlr3 WT MEFs for 38 of the 42 ISGs differentially expressed in WT and Tlr3−/− MEFs, whereas 4 ISGs were more strongly expressed in these cells than in Tlr3 WT MEFs (Figure 7A, Supplemental Figure 7A, Supplemental Table 3). Seven of the 38 ISGs downregulated in Tlr3−/− MEFs were also downregulated in TLR3-deficient human fibroblasts, but different ISGs were upregulated in mouse and human TLR3-deficient fibroblasts (Supplemental Figure 7B, Supplemental Table 4). As in human fibroblasts, an analysis of the 38 ISGs downregulated in Tlr3−/− MEFs with DAVID software (44) confirmed a significant downregulation of type I IFN signaling pathway genes and antiviral immune genes (Supplemental Table 5). We confirmed these findings by measuring basal levels of expression for several ISGs by RT-qPCR. Consistent with the human data, Tlr3−/− MEFs had lower levels of mRNA for various ISGs, including Ifit1, Ifit2, and Ifit3 (Figure 7B). Finally, we assessed the viral susceptibility of MEFs by measuring viral RNA levels after infection with VSV-WT and -M51R. Tlr3−/− MEFs were more susceptible to both VSV-WT and -M51R than Tlr3 WT MEFs, as high levels of VSV RNA were detected in Tlr3−/− MEFs as early as 5 hours after infection (Figure 7, C and D; Supplemental Figure 7, C and D). These data suggest that TLR3 signaling controls constitutive antiviral IFN immunity...
in both mouse and human fibroblasts, which use this mechanism to restrict infection with various viruses.

**Impaired basal IFN-β and intrinsic antiviral immunity in TLR3-deficient iPSC-derived cortical but not TG neurons.** We previously showed that TLR3 deficiency impairs cell-autonomous defense against HSV-1 infection in iPSC-derived cortical neurons and oligodendrocytes, but not astrocytes, neural stem cells, and TG neurons (25, 26). As with fibroblasts, prior treatment (but not treatment at the time of infection) of TLR3 pathway-deficient iPSC-derived cortical neurons and oligodendrocytes with recombinant IFN-α2b or -β, but not IFN-λ, protected them against HSV-1 replication (25, 26). We investigated whether our findings for fibroblasts also applied to cortical and TG neurons. We derived cortical and TG neurons from one healthy control iPSC line, one healthy hESC line, an iPSC line from a patient with AR complete TLR3 deficiency (26), and an isogenic TLR3-KO iPSC line that we generated by CRISPR/Cas9-mediated gene editing (Supplemental Figure 8, A and B) (49). As in SV-40 fibroblasts, virus-induced IFNB and IFNL1 induction occurred late, 16 and 24 hours after HSV-1 infection (Supplemental Figure 8, C and D). When cortical neurons
were infected with VSV-WT, VSV-M51R, and HSV-1, higher levels of viral replication were observed as early as 6 hours after infection in TLR3-deficient cells, confirming that TLR3 is essential for the control of HSV-1 in these cells, and showing that this receptor is also essential for control of the 2 types of VSV tested (Figure 8, A–C). By contrast, the replication of the 3 viruses was not higher in TG neurons lacking TLR3 than in the other cells (Supplemental Figure 8, E–G). TLR3 protein levels were undetectable in both patient-specific and isogenic TLR3-deficient iPSC-derived cortical neurons, as shown by Western blotting (Supplemental Figure 8A). We also assessed basal IFN-β protein secretion by cortical neurons in the Simoa assay (50). We showed that basal levels of IFN-β production were low in TLR3-deficient cells (Figure 8D). We further analyzed the transcriptomes of control iPSC-derived cortical neurons, comparing them with those of TLR3-deficient patient and isogenic TLR3-KO iPSC-derived cortical neurons. Consistent with our results for fibroblasts, TLR3-deficient cortical neurons had low levels of ISG mRNAs (Figure 8, E and F; and Supplemental Figure 9, A and B). The IFN mRNAs themselves were not detected by RNA-Seq. In total, we detected the expression of 734 ISGs in control cortical neurons in basal conditions. The mRNA levels for these genes were significantly lower in both TLR3-deficient patient and TLR3-KO cortical neurons than in control cells, for 243 of 265 and 283 of 311 differentially expressed ISGs, respectively, whereas 22 and 28 ISGs were upregulated in these cells relative to control cells (Supplemental Figure 9, C and D; and Supplemental Table 6). As many as 196 of the downregulated ISGs and 9 of the upregulated ISGs were common to TLR3-KO and TLR3-deficient patient neurons. An analysis with DAVID software (44) of the 196 ISGs with low basal levels of expression confirmed the significant downregulation of the genes controlled by the IFN-α/β-response pathway, and of antiviral genes in both TLR3-KO and TLR3-deficient cortical neurons (Supplemental Table 7). Collectively, these findings strongly suggest that TLR3 also controls constitutive levels of IFN-β, and thus, cell-intrinsic antiviral immunity, in human hPSC-derived cortical neurons. This process is crucial for infection control, at least for VSV and HSV-1 in vitro and, by inference, probably HSV-1 in vivo.

Discussion
We describe an unexpected role of TLR3 signaling in antiviral immunity: as a rheostat controlling constitutive low-level production of IFN-β, which is crucial for limiting viral replication at early stages in the viral infection of dermal fibroblasts and cortical neurons. IFN-β was previously thought to be the fibroblastic IFN because it was discovered in these cells, in which no other type I IFNs were detectable (51). In most other cells, it is the first IFN to be induced after viral infection, triggering the amplification of other IFNs via IRF7 (52). We discovered that the restriction of VSV growth in human fibroblasts was heavily dependent on the TLR3-dependent basal IFN-β production of these cells, rather than their recognition of VSV and the subsequent RIG-I-dependent induction of IFN-β. Basal IFN-β production is impaired in TLR3−/− and UNC-93B−/− fibroblasts, and these cells are therefore overwhelmed by VSV-WT and even M51R replication within as little as 6 hours after infection, before the RIG-I-dependent induction of IFN-β production in response to viral infection. This situation contrasts with that in healthy control fibroblasts, in which VSV replication and cell death are limited by basal IFN-β levels, which are higher not only than those in UNC-93B−/− and TLR3−/− cells, but also than those in NEMO−/−, STAT1−/−, and STAT2−/− cells. In human fibroblasts lacking TLR3 signaling (e.g., UNC-93B−/−, TLR3−/−, NEMO−/−), the impairment of constitutive low-level TLR3-dependent IFN-β production may reduce the responsiveness and intrinsic defenses of uninfected cells against viral infection, by reducing the basal level of expression of specific ISGs. In cells lacking IFN signaling responses (e.g., STAT1−/−, STAT2−/−), impaired responses to IFN-β result in lower levels of basal expression for ISGs, including TLR3 and STAT1. As a more general consequence, fibroblasts lacking TLR3 and IFN signaling are highly susceptible to infection with the 3 RNA viruses (VSV, hPIV3, EMCV) and the DNA virus (HSV-1) tested, regardless of the levels of IFN-β induction by these viruses. Similarly, TLR3-deficient iPSC-derived cortical neurons are highly susceptible to infection with VSV and HSV-1. Collectively, our data indicate that inborn errors of the TLR3 pathway impair basal and protective IFN-β antiviral immunity in human fibroblasts and cortical neurons.

We have shown that this TLR3 rheostat also operates in mouse fibroblasts. Previous studies have shown that Tlr3−/− mice are no more susceptible than their WT littermates to VSV, lymphocytic choriomeningitis virus, or reovirus (53), and that they are even more resistant to Punta Toro virus (54), influenza virus (55), and vaccinia virus (56). Mouse fibroblasts may not have been infected in the course of such experiments, or their contribution to host defense may be compensated by other cells. However, mouse TLR3 is required for antiviral immunity to mouse cytomegalovirus (57), respiratory syncytial virus (58), coxsackievirus group B serotype 3 (CVB3) (59), and coxsackievirus B4 (CVB4) viruses (60). The contribution of fibroblasts in these models is unknown. Other cell types in mice may also control basal IFN-β immunity through TLR3. Interestingly, the DNA sensor cGAS controls basal levels of IFNs and ISGs in mouse bone marrow–derived macrophages (61). It is therefore possible that TLR3 and cGAS control basal ISG levels in different cell types. In certain cell types, both may be required for basal antiviral immunity. Mouse cGAS is essential for defense against various infections, including HSV-1 infection (30). The genetic ablation of cGAS revealed that this protein was required for antiviral responses to both DNA viruses and RNA viruses in vivo (61). Future studies with single and double knockouts of TLR3 and cGAS in mice and humans may delineate the respective contributions of TLR3 and cGAS, as viral sensors versus rheostats of IFN immunity in host defense. Virus-induced IFN-α/β and IFN-γ production could be protective against viral infection in vivo, probably following the earliest stage of viral infection. The study of MDA5 and RIG-I in this context is also warranted by the identification of patients with MDA5 deficiency displaying selective vulnerable to respiratory viruses (62, 63). The identification of patients with cGAS, STING, or RIG-I deficiency could provide new insight into this aspect.

The natural TLR3 stimuli controlling basal IFN-β production in fibroblasts and cortical neurons remain unknown. In the absence of exogenous stimulation, endogenous ligands such as mRNAs or debris from necrotic cells can trigger TLR3 signaling in human dendritic cells (64) and murine macrophages (65), respec-

https://doi.org/10.1172/JCI134529
tively. Self-noncoding RNAs generated during cell damage and the microtubule regulator stathmin have been identified as endogenous agonists of TLR3 in human keratinocytes and in human astrocytes and microglia cells, respectively (66, 67). One or more of these known cell-endogenous agonists may activate TLR3 in fibroblasts, cortical neurons, and other cells, thereby contributing to basal IFN and ISG production. However, it remains possible that TLR3 can sustain basal activation in the absence of stimulation with any ligand. In any event, our study clearly demonstrates that TLR3 is essential for the maintenance of constitutive IFN-β immunity in human fibroblasts and cortical neurons, and this observation also applies to mouse fibroblasts. It may also operate in other CNS-resident cells, such as oligodendrocytes, in which the control of HSV-1 is also dependent on TLR3, contrasting with the situation in astrocytes, neural stem cells, and TG neurons (25, 26).

Constitutive TLR3 activity in the brain may also be important in the prevention of other neurological conditions via mechanisms that may or may not be related to IFN-mediated immunity (68, 69). While we cannot yet discern the respective roles of constitutive and virus-induced cell-intrinsic IFN immunity in the course of natural infection with HSV-1 in TLR3-deficient individuals, our findings provide a plausible molecular and cellular basis for HSE in patients with inborn errors of TLR3 immunity. They also suggest that IFN-α/β, rather than IFN-λ, are critical for protective immunity to HSV-1 in the CNS.

Our findings also suggest that TLR3-dependent cell-intrinsic constitutive IFN immunity may be a critical first line of defense against HSV-1 and perhaps other viruses in certain tissues, and its disruption may result in tissue-specific severe viral infections in various organs. Patients with TLR3 deficiency may also be more susceptible to diseases other than HSE. This was confirmed by our recent identification of 3 unrelated patients with TLR3 mutations and severe influenza pneumonia (70), a finding that is consistent with TLR3 being a major IFN-β- and IFN-λ-inducing receptor in human and mouse pulmonary epithelial cells (PECs), in which large amounts of IFN-λ may be produced with potent antiviral activity (70, 71). Furthermore, a deleterious TLR3 mutation has also been found in a patient with varicella zoster virus ophthalmic neuritis (72). Overall, our findings indicate that TLR3 controls baseline tone of IFN-β and IFN-λ in dermal fibroblasts and of IFN-β in cortical neurons (both cell types respond to IFN-β but not IFN-λ). They also suggest that TLR3 may control baseline levels of IFN-β and/or IFN-λ in PECs (which respond to both IFN-β and IFN-λ). The genetic dissection of various viral diseases, including coronavirus disease 2019 (COVID-19) (73–75), may help to delineate the roles of human TLR3 and other IFN-inducing sensors in host defense. It also seems likely that deficiencies of other type I IFN responsiveness circuit genes (e.g., IRF7, IRF9, STAT1, STAT2, IFNAR1, IFNAR2) render patients prone to a broad spectrum of viral diseases, other than the previously reported phenotypes including severe influenza pneumonia (IRF7, IRF9), HSE (IFNAR1, STAT1), and severe adverse reactions to live attenuated viral vaccines (IRF9, STAT1, STAT2, IFNAR1, IFNAR2) (12, 17, 40, 76–79), partly due to the low basal levels of IFN-β, IFN-λ, and ISG in tissue-specific cells. Our findings highlight the importance of host cell-intrinsic and constitutive, as opposed to pathogen-induced, IFN and ISG immunity in antiviral defenses, particularly during early stages of viral infection (80–82). Our findings also suggest that TLR3 may govern the first line of broad antiviral responses in some cell types, such as fibroblasts, cortical neurons, and perhaps PECs, or even more broadly in certain tissues or organs, such as the CNS and lungs in particular, as opposed to governing immunity to specific viruses, such as HSV-1, in various cells, tissues, and organs.

**Methods**

**Cells and viruses.** Primary fibroblasts were isolated from skin biopsy specimens from patients with AR UNC-93B, AR STAT1, XR NEMO, and AR TLR3 deficiencies and healthy controls, as previously described (9, 11, 13, 41). The fibroblasts were immortalized by transfection with the SV-40 large T antigen and maintained in DMEM supplemented with 10% FBS.

Cells stably expressing shRNAs against RIG-1 and MAVS were generated by transduction with shRNA-expressing retroviral particles (Santa Cruz Biotechnology). Stably transfected cell lines were generated by transfecting TLR3−/− or UNC-93B−/− fibroblasts with TLR3 or UNC-93B WT or empty vector, with Lipofectamine 2000 (Invitrogen). Transfectants were selected in DMEM containing 5 μg/mL blasticidin (Invitrogen).

VSV, Indiana strain, WT, and M51R mutant (harboring a substitution of an arginine residue in place of the methionine in position 51 of the matrix (M) protein) were provided by Pierre Lebon and have been described elsewhere (10, 39, 83–85). MEFs were generated from 14-day-old WT and Tlr3−/− embryos (86), and maintained in DMEM supplemented with 10% FBS.

**Cell culture of iPSCs and hESCs (together referred to as hPSCs), and neuronal induction and differentiation.** Control MRC5 and TLR3−/− patient-specific iPSC lines were reprogrammed with a nonintegrating Sendai viral vector, as previously described (26). All hPSC lines were used at passage 20–50, and were maintained on vitronectin with Essential 8 medium (Fisher Scientific), with twice-weekly passaging with EDTA (87). The HPSC lines used here were as follows: TLR3−/− patient-specific iPSCs, control iPSCs MRC5, isogenic MRC5 TLR3 KO iPSCs, and a control hESC line H9 (WA-09) (26). All cell lines were karyotyped to ensure genomic integrity and weekly tests for mycoplasma were performed. TG neuron and cortical neuron differentiation was performed as previously described (26).

**Cell stimulation.** SV-40 fibroblasts were plated at a density of 10⁴ cells per well in a 24-well plate and were incubated overnight. Polyinosinic-polycytidylc acid (poly(I:C); Amersharm) was added to the culture medium at a concentration of 25 μg/mL, transfected with the RIG-1 agonist, 7sk-as at a concentration of 0.45 ng, or with 25 μg of poly(I:C), with Lipofectamine 2000 (Invitrogen), or infection with VSV at the indicated MOIs, and the culture medium was harvested after 24 hours of stimulation. Cytokine concentrations in culture medium were determined by ELISA.

**Measurement of cytokine production.** IFN-β production was assessed in an enzyme-linked immunosorbent assay (ELISA; TFB Fujirebio). For IFN-λ determinations, culture supernatants were incubated for 2 hours in plates coated with 1 μg/mL monoclonal anti-human IL29 antibody (R&D Systems). A biotinylated monoclonal secondary antibody directed against human IL-29 (R&D Systems) and streptavidin peroxidase were added, together with TMB (3,3′,5,5′-tetramethylbenzidine). The signal at 450 nm was then read with a plate fluorescence reader.
Immunoblotting. Cells were lysed in NP40 lysis buffer (280 mM NaCl, 50 mM Tris pH 8, 0.2 mM EDTA, 2 mM EGTA, 10% glycerol, 0.5% NP40) supplemented with 1 mM DTT, 5 mM Na_3VO_4, and Complete protease inhibitor cocktail (Roche). The protein lysate was subjected to SDS-PAGE and the bands obtained were transferred to a PVDF membrane, which was probed with unconjugated rabbit anti-RIG-I (Cell Signaling, catalog 3743), goat anti-MAVS (Santa Cruz Biotechnology, catalog sc-365333), TLR3 (R&D Systems, catalog 1487) and HRP-conjugated secondary antibodies. A β-tubulin antibody (MilliporeSigma, catalog T4026) and a GAPDH (Santa Cruz Biotechnology, catalog sc-365062) antibody were used as loading controls.

For the detection of dsRNA in VSV-infected cells, SV-40 fibroblasts were plated as described above, with VSV at a MOI of 10 for 8 hours. RNA was isolated with TRIzol reagent (Invitrogen), according to the manufacturer’s protocol. We subjected 30 μg total RNA to electrophoresis in a 1.5% agarose/TBE gel, and the bands were then transferred to a nylon membrane (Hybond N+, GE Healthcare). The RNA was fixed by ultraviolet irradiation, probed with the anti–dsRNA antibody K1, and the blot was developed for enhanced chemiluminescence (Pico ECL, Pierce).

Viral assays. SV-40–transformed fibroblasts were plated at a density of 10^5 cells per well in 24-well plates. For one-step growth curves, the cells were incubated with VSV-WT and -M51R, hPIV3, EMCV, or HSV-1 at the indicated MOI for 30 minutes or 1 hour, washed twice in PBS, and then transferred to fresh DMEM. Virus samples were collected at the indicated times and the viral titer was determined by 50% tissue culture infective dose (TCID_50) assays on Vero E6 cells (for VSV and hPIV3), according to the Reed and Muench calculation (13), or by qPCR methods for EMCV (88), determinations of ICP27 mRNA levels for HSV-1, and determinations of VSV-G mRNA levels for VSV.

For coinfection experiments, cells were infected with VSV-WT at a MOI of 3 and with VSV-M51R at a MOI of 1 in DMEM supplemented with 10% FBS for 24 hours. VSV-WT and -M51R were inactivated by exposure to ultraviolet light for 10 minutes at a distance of 15 cm. Cytokine production was measured in the culture medium by ELISA.

For IFN neutralization experiments, cells were cultured in the presence of neutralizing polyclonal antibodies against IFN-α or -β (PBL), replaced daily for 3 days. They were then infected with VSV-WT or -M51R at a MOI of 3, as described above. Samples were collected at the times indicated and titered on Vero cells.

Cytotoxicity assays. Cells were plated at a density of 2 × 10^4 cells per well in 96-well plates, in DMEM with or without IFN-α and -β (PBL), replaced daily for 3 days. They were then infected with VSV-WT or -M51R at a MOI of 3, as described above. Samples were harvested at the indicated times and titered on Vero cells.

Determinations of mRNA levels by RT-qPCR. Total RNA was extracted from cells with TRIzol (Invitrogen) or the RNeasy kit (Qiagen). Samples were treated with DNase at 37°C for 1 hour and cleaned by passage through an RNeasy column (Qiagen). Reverse transcriptase-PCR was performed with random hexamers (Applied Biosystems). RT-qPCR was performed with Applied Biosystems TaqMan assays, using the β-glucuronidase (GUS) housekeeping gene for normalization, or in SYBR Green assays with the GAPDH (human) or RPL19 (mouse) housekeeping gene for normalization. Results are expressed according to the ΔΔCT method, as described by the manufacturer.

RNA sequencing and analysis. Total RNA was extracted from human primary fibroblasts, C57BL/6 mouse primary fibroblasts, or hPSC-derived cortical neurons. RNA samples were treated with DNase (Ambion) to remove residual genomic DNA. RNA-Seq libraries were prepared with the Illumina RiboZero Stranded Total RNA Library Prep Kit (Illumina) and sequenced on the Illumina NextSeq platform in the 150 nt with paired-end configuration. We sequenced 3 (human samples) or 2 (mouse samples) technical replicates for each sample. The raw sequencing data is available under National Center for Biotechnology Information Sequence Read Archive (NCBI-SRA) accession number SRP288648.

The RNA-Seq FASTQ raw data were inspected with multiQC v1.6 to ensure that they were of high quality (89). The sequencing reads of human and mouse samples were mapped onto the UCSC human reference genome GRCh37/hg19 and the UCSC mouse reference genome GRCm38/mmc10, respectively (90), with STAR aligner v2.6 (91). The quality of each mapped alignment in BAM files was evaluated with RSeQC (92). Reads were quantified to determine the number of gene-level read counts forming the read alignment, with featureCounts v1.6.0 and GENCODE GRCh37.p13 human gene annotation v19 and GENCODE GRCm38.p6 mouse gene annotation M19, respectively (93, 94). The gene-level read counts were normalized and log_2-transformed by DESeq2 to obtain the gene expression value for all genes and all samples (95).

We extracted expression data for 905 ISGs based on our previous IFN-stimulated microarray data analysis (13). Differential ISG expression was analyzed by applying TMM normalization and gene-wise generalized linear model regression in edgeR (96). The ISGs displaying significant differential expression were selected on the basis of a FDR < 0.05. We used ComplexHeatmap (97) to plot a heatmap of the fold-change in gene expression. Gene set enrichment analysis was performed with Ingenuity Pathway Analysis (IPA) (98) and DAVID (44) software.

Conditioned medium experiments. Conditioned culture medium was harvested from healthy control, TLR3^-/-, or UNC-93B^-/- unstimulated cell cultures after 2 days of culture. Cell debris was removed by centrifugation. Healthy control, TLR3^-/-, UNC-93B^-/-, or STAT1^-/- fibroblasts were then cultured in fresh DMEM. The conditioned culture supplemented with 100 U neutralizing antibodies against IFN-β or -α or normal sheep serum (isotype control) was added to the culture medium of the cells, and was maintained in the medium for 18 hours. RNA was isolated for RT-qPCR, and VSV growth was measured at the time points indicated.

Gene editing. Gene-editing experiments were performed as previously described (99). Briefly, guide RNA (gRNA) sequences were generated with the CRISPR design tool (http://crispr.mit.edu/). GTATC-GAATCAAAATTAAG was selected as the guide sequence. Forward and reverse oligonucleotides for each gRNA were then inserted into the MLM3636 vector (Addgene, 43860). We electroporated 2 million hPSCs with 20 μg of Cas9-GFP plasmid and 5 μg gRNA plasmid mixed in electroporation buffer (BTX, catalog 49-0805). Green cells were sorted by FACS 48 hours after electroporation. About 50,000 cells with a moderate GFP fluorescence intensity were cultured, plated at clonal density in 96-well plates, and amplified. Genomic DNA was
then extracted from each clone and Sanger sequencing for TLR3 was performed. Forward: 5′-CAACACTCCACCTCATAcT-3′; reverse: 5′-CAATTGAAAGAATGGTCCCCAGAc-3′. The TLR3-KO line used in this study carries a homozygous insertion that leads to a frameshift at amino acid position 210 and a premature stop codon 17 amino acids later (c. 628A>AA; p. K210fs17*).

Simoa assay. IFN-β protein levels were quantified in a digital ELISA (Simoa, Quanterix) developed with the Quanterix Homebrew kit, as previously described (50).

Statistics. Data are expressed as the mean of at least 3 biological replicates ± SD unless otherwise indicated, or are representative of 3 independent experiments. For most data, linear mixed models were used for log-transformed relative values, to account for repeated measurements. The difference between cases and controls was assessed with a likelihood ratio test. Analysis was performed with the nlme package of R software. Where indicated, 1-way ANOVA tests or log-transformations followed by 1-way ANOVA tests were used for statistical analysis. Data were analyzed in PRISM7. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Study approval. All experiments were conducted in accordance with local regulations and with the approval of the institutional review boards of The Rockefeller University and Institut National de la Santé et de la Recherche Médicale (INSERM).

Author contributions. DG, MJC, OH and JC performed the experiments. DG, MJC, PZ, and JC analyzed the data. VB, MH, XM, YI, AC, VSS, BB, LL, GC, JM, EA, EJ, DC, IM, LA, SH, GAS, LN, DD, LS helped design the study and performed some of the experiments. MSD provided MEF cells. JLC and SYZ supervised the study. DG, MJC, JLC and SYZ wrote the manuscript. All authors contributed and edited the manuscript.

Acknowledgments. We thank the patients and their families for their participation. We thank the members of both branches of the St. Giles Laboratory of Human Genetics of Infectious Diseases, in particular Tatiana Kochetkov, for expertise and assistance with cell culture, Dusan Bogunovic for invaluable discussions and advice, and Dominick Papandrea, Cécile Patissier, and Yelena Nemirovskaya for administrative assistance. We thank Pierre Lebon (Laboratory of Virology, Paris University, Assistance Publique-Hôpitaux de Paris, Cochin Hospital) for providing us with VSV and technical advice. This work was funded in part by the National Center for Advancing Translational Sciences, NIH Clinical and Translation-Alization Science Award program (UL1TR001866), NIH (R01NS072381, R01AI088364, and R21AI156163), the French National Research Agency (ANR) under the “Investments for the future” program (ANR-10-IHU-01), Integrative Biology of Emerging Infectious Diseases Laboratoire d’Excellence (ANR-10-LABX-62-IBEID), and grants ANR-14-CE14-0008-01 and ANR-18-CE15-0020-02, The Rockefeller University, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris Descartes University, and the St. Giles Foundation. DG is supported by the Charles H. Revson Senior Fellowship in Biomedical Sciences and the National Natural Science Foundation of China (grant 31970855). IM is supported by KU Leuven C1 grant C16/18/007 and Fonds Wetenschappelijk Onderzoek Vlaanderen grant G0C8517N.


